Tioma Therapeutics

The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
Endpoints
Tue, 08/16/16 - 11:16 am
GSK
Roche
Novo Nordisk
Tioma Therapeutics
CD47
immuno-oncology